Artery Research
Volume 3, Issue 1 , Pages 9-16 , February 2009

Marfan and Marfan-like syndromes

  • J. De Backer

      Affiliations

    • Department of Medical Genetics, University Hospital Ghent, De Pintelaan 185, 9000 Ghent, Belgium
    • Department of Cardiology, University Hospital Ghent, De Pintelaan 185, 9000 Ghent, Belgium
    • Corresponding Author InformationCorresponding author at: Department of cardiology, University Hospital Ghent, De Pintelaan 185, 9000 Ghent, Belgium. Tel.: +32 9 332 56 27; fax: +32 9 332 49 70.
    • ,
  • B. Loeys

      Affiliations

    • Department of Medical Genetics, University Hospital Ghent, De Pintelaan 185, 9000 Ghent, Belgium
    • ,
  • A. De Paepe

      Affiliations

    • Department of Medical Genetics, University Hospital Ghent, De Pintelaan 185, 9000 Ghent, Belgium

Received 23 October 2008 ,Revised 8 January 2009 ,Accepted 19 January 2009.

References 

  1. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991 Jul 25;352(6333):337–339
  2. Rosenbloom J, Abrams WR, Mecham R. Extracellular matrix 4: the elastic fiber. FASEB J. 1993 Oct;7(13):1208–1218
  3. Pereira L, Andrikopoulos K, Tian J, Lee SY, Keene DR, Ono R, et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet. 1997 Oct;17(2):218–222
  4. Pereira L, Lee SY, Gayraud B, Andrikopoulos K, Shapiro SD, Bunton T, et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3819–3823
  5. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL, et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest. 2004 Jul;114(2):172–181
  6. Bunton TE, Biery NJ, Myers L, Gayraud B, Ramirez F, Dietz HC. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res. 2001 Jan 19;88(1):37–43
  7. Dallas SL, Keene DR, Bruder SP, Saharinen J, Sakai LY, Mundy GR, et al. Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo. J Bone Miner Res. 2000 Jan;15(1):68–81
  8. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF. Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol. 1995 Oct;131(2):539–549
  9. Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J. Latent transforming growth factor-beta binding proteins (LTBPs) – structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev. 1999 Jun;10(2):99–117
  10. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem. 2003 Jan 24;278(4):2750–2757
  11. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003 Mar;33(3):407–411
  12. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996;62(4):417–426
  13. Tiecke F, Katzke S, Booms P, Robinson PN, Neumann L, Godfrey M, et al. Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype–phenotype correlations in FBN1 exons 24–40. Eur J Hum Genet. 2001 Jan;9(1):13–21
  14. Kainulainen K, Karttunen L, Puhakka L, Sakai L, Peltonen L. Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome. Nat Genet. 1994 Jan;6(1):64–69
  15. Putnam EA, Cho M, Zinn AB, Towbin JA, Byers PH, Milewicz DM. Delineation of the Marfan phenotype associated with mutations in exons 23–32 of the FBN1 gene. Am J Med Genet. 1996 Mar 29;62(3):233–242
  16. Black C, Withers AP, Gray JR, Bridges AB, Craig A, Baty DU, et al. Correlation of a recurrent FBN1 mutation (R122C) with an atypical familial Marfan syndrome phenotype. Hum Mutat. 1998;(Suppl. 1):S198–S200
  17. De Backer J, Loeys B, Leroy B, Coucke P, Dietz H, De Paepe A. Utility of molecular analyses in the exploration of extreme intrafamilial variability in the Marfan syndrome. Clin Genet. 2007 Sep;72(3):188–198
  18. Judge DP, Dietz HC. Marfan's syndrome. Lancet. 2005 Dec 3;366(9501):1965–1976
  19. Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol. 1989;64(8):507–512
  20. Apter JT. Correlation of visco-elastic properties with microscopic structure of large arteries. IV. Thermal responses of collagen, elastin, smooth muscle, and intact arteries. Circ Res. 1967 Dec;21(6):901–918
  21. Pyeritz RE. Marfan syndrome: current and future clinical and genetic management of cardiovascular manifestations. Semin Thorac Cardiovasc Surg. 1993 Jan;5(1):11–16
  22. Roman MJ, Rosen SE, Kramer-Fox R, Devereux RB. Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. J Am Coll Cardiol. 1993;22(5):1470–1476
  23. Dapunt OE, Galla JD, Sadeghi AM, Lansman SL, Mezrow CK, de Asla RA, et al. The natural history of thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 1994 May;107(5):1323–1332[discussion 32–3]
  24. Pyeritz RE. Genetics and cardiovascular disease. In:  Braunwald E editors. Cardiovascular disease. Philadelphia: Saunders; 1992;p. 1641–1643
  25. Groenink M, Lohuis TA, Tijssen JG, Naeff MS, Hennekam RC, van der Wall EE, et al. Survival and complication free survival in Marfan's syndrome: implications of current guidelines. Heart. 1999;82(4):499–504
  26. Legget ME, Unger TA, O'Sullivan CK, Zwink TR, Bennett RL, Byers PH, et al. Aortic root complications in Marfan's syndrome: identification of a lower risk group. Heart. 1996 Apr;75(4):389–395
  27. Silverman DI, Gray J, Roman MJ, Bridges A, Burton K, Boxer M, et al. Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J Am Coll Cardiol. 1995;26(4):1062–1067
  28. Jondeau G, Boutouyrie P, Lacolley P, Laloux B, Dubourg O, Bourdarias JP, et al. Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome. Circulation. 1999;99(20):2677–2681
  29. Adams JN, Brooks M, Redpath TW, Smith FW, Dean J, Gray J, et al. Aortic distensibility and stiffness index measured by magnetic resonance imaging in patients with Marfan's syndrome. Br Heart J. 1995;73(3):265–269
  30. Groenink M, de Roos A, Mulder BJ, Verbeeten B, Timmermans J, Zwinderman AH, et al. Biophysical properties of the normal-sized aorta in patients with Marfan syndrome: evaluation with MR flow mapping. Radiology. 2001;219(2):535–540
  31. Hirata K, Triposkiadis F, Sparks E, Bowen J, Boudoulas H, Wooley CF. The Marfan syndrome: cardiovascular physical findings and diagnostic correlates. Am Heart J. 1992;123(3):743–752
  32. Jeremy RW, Huang H, Hwa J, McCarron H, Hughes CF, Richards JG. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol. 1994;74(4):369–373
  33. Baumgartner D, Baumgartner C, Matyas G, Steinmann B, Loffler-Ragg J, Schermer E, et al. Diagnostic power of aortic elastic properties in young patients with Marfan syndrome. J Thorac Cardiovasc Surg. 2005 Apr;129(4):730–739
  34. Pyeritz RE, Wappel MA. Mitral valve dysfunction in the Marfan syndrome. Clinical and echocardiographic study of prevalence and natural history. Am J Med. 1983 May;74(5):797–807
  35. De Backer J, Loeys B, Devos D, Dietz H, De Sutter J, De Paepe A. A critical analysis of minor cardiovascular criteria in the diagnostic evaluation of patients with Marfan syndrome. Genet Med. 2006 Jul;8(7):401–408
  36. Nollen GJ, van Schijndel KE, Timmermans J, Groenink M, Barentsz JO, van der Wall EE, et al. Pulmonary artery root dilatation in Marfan syndrome: quantitative assessment of an unknown criterion. Heart. 2002 May;87(5):470–471
  37. Dietz HC, Pyeritz RE. Marfan syndrome and related disorders. In:  Scriver CR,  Beaudet A,  Sly WS,  Valle D editor. The metabolic and molecular bases of inherited diseases. 1995;p. 5287–5311
  38. Finkbohner R, Johnston D, Crawford ES, Coselli J, Milewicz DM. Marfan syndrome: long-term survival and complications after aortic aneurysm repair. Circulation. 1995 February 1;91(3):728–733
  39. Engelfriet PM, Boersma E, Tijssen JG, Bouma BJ, Mulder BJ. Beyond the root: dilatation of the distal aorta in the Marfan syndrome. Heart. 2006 Feb 17;
  40. van Ooijen B. Marfan's syndrome and isolated aneurysm of the abdominal aorta. Br Heart J. 1988 Jan;59(1):81–84
  41. Pruzinsky MS, Katz NM, Green CE, Satler LF. Isolated descending thoracic aortic aneurysm in Marfan's syndrome. Am J Cardiol. 1988 May 1;61(13):1159–1160
  42. Nollen GJ, Groenink M, Tijssen JG, Van Der Wall EE, Mulder BJ. Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome. Eur Heart J. 2004 Jul;25(13):1146–1152
  43. Kawamoto S, Bluemke DA, Traill TA, Zerhouni EA. Thoracoabdominal aorta in Marfan syndrome: MR imaging findings of progression of vasculopathy after surgical repair. Radiology. 1997 Jun;203(3):727–732
  44. Nollen GJ, Meijboom LJ, Groenink M, Timmermans J, Barentsz JO, Merchant N, et al. Comparison of aortic elasticity in patients with the Marfan syndrome with and without aortic root replacement. Am J Cardiol. 2003 Mar 1;91(5):637–640
  45. Chatrath R, Beauchesne LM, Connolly HM, Michels VV, Driscoll DJ. Left ventricular function in the Marfan syndrome without significant valvular regurgitation. Am J Cardiol. 2003 Apr 1;91(7):914–916
  46. Savolainen A, Nisula L, Keto P, Hekali P, Viitasalo M, Kaitila I, et al. Left ventricular function in children with the Marfan syndrome. Eur Heart J. 1994;15(5):625–630
  47. Porciani MC, Giurlani L, Chelucci A, Pepe G, Giusti BH, Brunelli T, et al. Diastolic subclinical primary alterations in Marfan syndrome and Marfan-related disorders. Clin Cardiol. 2002 Sep;25(9):416–420
  48. Das BB, Taylor AL, Yetman AT. Left ventricular diastolic dysfunction in children and young adults with Marfan syndrome. Pediatr Cardiol. 2006 Mar–Apr;27(2):256–258
  49. De Backer JF, Devos D, Segers P, Matthys D, Francois K, Gillebert TC, et al. Primary impairment of left ventricular function in Marfan syndrome. Int J Cardiol. 2005 Nov 25;
  50. Rossi-Foulkes R, Roman MJ, Rosen SE, Kramer-Fox R, Ehlers KH, O'Loughlin JE, et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol. 1999;83(9):1364–1368
  51. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994;330(19):1335–1341
  52. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117–121
  53. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med. 2008 Jun 26;358(26):2787–2795
  54. Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J. 2007 Oct;154(4):624–631
  55. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005 Mar;37(3):275–281
  56. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006 Aug 24;355(8):788–798
  57. Williams JA, Loeys BL, Nwakanma LU, Dietz HC, Spevak PJ, Patel ND, et al. Early surgical experience with Loeys–Dietz: a new syndrome of aggressive thoracic aortic aneurysm disease. Ann Thorac Surg. 2007 Feb;83(2):S757–S763[discussion S85–90]
  58. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers–Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342(10):673–680
  59. Oderich GS, Panneton JM, Bower TC, Lindor NM, Cherry KJ, Noel AA, et al. The spectrum, management and clinical outcome of Ehlers–Danlos syndrome type IV: a 30-year experience. J Vasc Surg. 2005 Jul;42(1):98–106
  60. Boutouyrie P, Germain DP, Fiessinger JN, Laloux B, Perdu J, Laurent S. Increased carotid wall stress in vascular Ehlers–Danlos syndrome. Circulation. 2004 Mar 30;109(12):1530–1535
  61. Coucke PJ, Willaert A, Wessels MW, Callewaert B, Zoppi N, De Backer J, et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet. 2006 Mar 19;
  62. Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, et al. Mutations in transforming growth factor-{beta} receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation. 2005 July 26;112(4):513–520
  63. Zhu L, Vranckx R, Van Kien PK, Lalande A, Boisset N, Mathieu F, et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet. 2006 Mar;38(3):343–349
  64. Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet. 2007 Dec;39(12):1488–1493
  65. Lalande A, Khau Van Kien P, Walker PM, Zhu L, Legrand L, Claustres M, et al. Compliance and pulse wave velocity assessed by MRI detect early aortic impairment in young patients with mutation of the smooth muscle myosin heavy chain. J Magn Reson Imaging. 2008 Nov;28(5):1180–1187
  66. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension. 2005 Jun;45(6):1050–1055
  67. Mills P, Leech G, Davies M, Leathan A. The natural history of a non-stenotic bicuspid aortic valve. Br Heart J. 1978 Sep;40(9):951–957
  68. de Sa M, Moshkovitz Y, Butany J, David TE. Histologic abnormalities of the ascending aorta and pulmonary trunk in patients with bicuspid aortic valve disease: clinical relevance to the Ross procedure. J Thorac Cardiovasc Surg. 1999 Oct;118(4):588–594
  69. Fedak PW, Verma S, David TE, Leask RL, Weisel RD, Butany J. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation. 2002 Aug 20;106(8):900–904
  70. Hahn RT, Roman MJ, Mogtader AH, Devereux RB. Association of aortic dilation with regurgitant, stenotic and functionally normal bicuspid aortic valves. J Am Coll Cardiol. 1992 Feb;19(2):283–288
  71. Cecconi M, Manfrin M, Moraca A, Zanoli R, Colonna PL, Bettuzzi MG, et al. Aortic dimensions in patients with bicuspid aortic valve without significant valve dysfunction. Am J Cardiol. 2005 Jan 15;95(2):292–294
  72. Gurvitz M, Chang RK, Drant S, Allada V. Frequency of aortic root dilation in children with a bicuspid aortic valve. Am J Cardiol. 2004 Nov 15;94(10):1337–1340
  73. Basso C, Boschello M, Perrone C, Mecenero A, Cera A, Bicego D, et al. An echocardiographic survey of primary school children for bicuspid aortic valve. Am J Cardiol. 2004 Mar 1;93(5):661–663
  74. Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol. 1997 Dec;30(7):1809–1812
  75. Emanuel R, Withers R, O'Brien K, Ross P, Feizi O. Congenitally bicuspid aortic valves. Clinicogenetic study of 41 families. Br Heart J. 1978 Dec;40(12):1402–1407
  76. Goh D, Han L, Judge DP, Dietz H. Linkage of familial bicuspid aortic valve with aortic aneurysm to chromosome 15q. Am Soc Hum Genet. 2002;71:A239
  77. Loscalzo M, Goh D, Spevak PJ. A prospective analysis of the inheritance, pathogenesis and natural history of bicuspid aortic valve with thoracic aortic aneurysm. Am Soc Hum Genet. 2004;
  78. Beighton P. The dominant and recessive forms of cutis laxa. J Med Genet. 1972 Jun;9(2):216–221
  79. Szabo Z, Crepeau MW, Mitchell AL, Stephan MJ, Puntel RA, Yin Loke K, et al. Aortic aneurysmal disease and cutis laxa caused by defects in the elastin gene. J Med Genet. 2006 Mar;43(3):255–258

PII: S1872-9312(09)00004-0

doi: 10.1016/j.artres.2009.01.003

Artery Research
Volume 3, Issue 1 , Pages 9-16 , February 2009

Article Tools